Recent developments

at Tullis and our portfolio companies

News

Keeping you current on new and follow-on investments, portfolio product and service milestones, publications and events, management and board transitions, and other developments in Tullis funds.

March

23

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

Pre-clinical trial demonstrates the ability of nVNS to decrease the amount of brain injury,...

21

electroCore’s Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study

ROCKAWAY, N.J., March 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Record AVISE® CTD Volume in 2022 SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a...

8

electroCore Announces Fourth Quarter and Full Year 2022 Financial Results

Record full year 2022 net sales of $8.6 million increased 58% over $5.5 million for...

28

ATEC Reports Record Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Highlights

CARLSBAD, Calif.–(BUSINESS WIRE)– Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative solutions dedicated to...

21

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

DENVER and CHICAGO, February 21, 2023 – TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”),...

21

electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa

ROCKAWAY, N.J., Feb. 21, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage...

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes...

16

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

ROCKAWAY, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine...

14

electroCore Announces Reverse Stock Split

ROCKAWAY, N.J., Feb. 14, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage...

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

SAN DIEGO, Jan. 23, 2023 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions,...

17

electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update

ROCKAWAY, N.J., Jan. 17, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage...

Recent developments

News

March

23

electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

March

21

electroCore’s Truvaga Users Reported Improved Stress, Anxiety, Sleep, Energy and Mood in Recent Focus Group Study

March

20

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

March

8

electroCore Announces Fourth Quarter and Full Year 2022 Financial Results

February

28

ATEC Reports Record Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Highlights

February

21

TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

February

21

electroCore, Inc. Announces Exclusive Distribution Agreement with Byond Healthcare Pty Ltd, South Africa

February

16

TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

February

16

electroCore Expands Intellectual Patent Portfolio for nVNS Technology

February

14

electroCore Announces Reverse Stock Split

January

23

Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors

January

17

electroCore Announces Expected Record 4Q 2022 Revenue of $2.5M; Provides Business Update